The estimated Net Worth of Eugene Seymour is at least $1.98 Million dollars as of 22 September 2015. Eugene Seymour owns over 104,384 units of NanoViricides Inc stock worth over $1,982,420 and over the last 9 years Eugene sold NNVC stock worth over $0.
Eugene has made over 1 trades of the NanoViricides Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Eugene exercised 104,384 units of NNVC stock worth $36,534 on 22 September 2015.
The largest trade Eugene's ever made was exercising 104,384 units of NanoViricides Inc stock on 22 September 2015 worth over $36,534. On average, Eugene trades about 52,192 units every 0 days since 2015. As of 22 September 2015 Eugene still owns at least 1,287,286 units of NanoViricides Inc stock.
You can see the complete history of Eugene Seymour stock trades at the bottom of the page.
Eugene's mailing address filed with the SEC is 1 CONTROLS DRIVE, , SHELTON, CT, 06484.
Over the last 15 years, insiders at NanoViricides Inc have traded over $1,608,110 worth of NanoViricides Inc stock and bought 1,581,444 units worth $2,879,162 . The most active insiders traders include Milton Boniuk, Anil Diwan, and Pharma, Inc. Theracour. On average, NanoViricides Inc executives and independent directors trade stock every 77 days with the average trade being worth of $126,113. The most recent stock trade was executed by Milton Boniuk on 11 November 2015, trading 25,000 units of NNVC stock currently worth $30,000.
nanoviricides, inc., a nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. its products pipeline includes herpecide dermal topical and eye drops for the treatment of shingles, phn, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and herpecide intraocular injection for viral acute retinal necrosis. the company also develops flucide broad-spectrum anti-influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; nanoviricide eye drops for viral diseases of the external eye; denguecide for treatment of all types of dengue viruses; and hivcide that is an escape-resistant anti-hiv nanoviricide. in addition, it is also involved in research and development of other nanoviricides drug projects for treatment of different viruses and indications; and herpecide program expansion drug projects for different herpes viruses for different indications. nanovir
NanoViricides Inc executives and other stock owners filed with the SEC include: